Funxional

Funxional Therapeutics Ltd. develops pharmaceutical products in the UK. Its candidate products include BN83470 for the treatment of respiratory indications, initially for asthma; BN83250 for the prevention of surgical adhesion formation and stroke treatment; and FX125L, an orally available small molecule belonging to a therapeutic class known as broad-spectrum chemokine inhibitors. The company also offers early preclinical programs focused on Alzheimer's disease, autoimmune diseases, pain, and diabetes. Funxional Therapeutics Ltd. was founded in 2005 and is headquartered in Cambridge, UK.